NCT07529938Completed
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
Mavacamten for Improving Cardiac Function and Clinical Outcomes in Adult Patients With Obstructive Hypertrophic Cardiomyopathy: A Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
This retrospective cohort study aims to evaluate the clinical efficacy and safety of mavacamten in adult patients with obstructive hypertrophic cardiomyopathy (oHCM). A total of 222 patients were included and categorized based on treatments received in routine clinical practice into a mavacamten group and a standard therapy group. The primary outcome is the change in resting left ventricular outflow tract (LVOT) gradient at Week 30. Secondary outcomes include changes in Valsalva LVOT gradient, New York Heart Association (NYHA) functional class, cardiac biomarkers, and echocardiographic parameters. Safety outcomes include adverse events and left ventricular systolic dysfunction. This study provides real-world evidence on the effectiveness and safety of mavacamten in Chinese patients with oHCM.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 222 (actual)
- First submitted
- 8 Apr 2026
- Start date
- 1 Jan 2024
- Primary completion date
- 30 May 2025
- Lead sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07529938
What you commit to
- Study type: Observational
- Participants enrolled: 222
- From 1 Jan 2024 to the primary completion date, 30 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Septal reduction therapy within 6 months prior to enrollment
Other illness
- Known hypersensitivity to mavacamten or its components
- Presence of other conditions requiring long-term anticoagulation
- Any condition deemed unsuitable by the investigator
Lab values
- Left ventricular ejection fraction (LVEF) \<55%
Other
- Pregnancy or breastfeeding
Who the study is looking for
- Age ≥18 years
- Diagnosis of hypertrophic cardiomyopathy
- NYHA functional class II-III
- First-time treatment with mavacamten
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Central China Cardiovascular Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.